1. What happened
Multi-year agreement supplies journal text and multimedia from 1990 onward to inform clinical answers. Date is public announcement. Do not treat the simultaneous financing valuation as a content-license price. Issuer separately describes models trained on NEJM content, but the new license's full training terms are not published. Funding valuation is not content-license consideration.
2. Buyer / seller
OpenEvidence is the AI buyer or model-development side. NEJM Group owns or contributes the proprietary corpus.
3. Economics
No arrangement-specific consideration established in the inspected announcement. Economics scope: No data-license value is estimated. Aggregate corporate revenue, financing valuations, settlement payments and catalogue capacity are not treated as this arrangement’s price.. Strategic Signal has not estimated undisclosed consideration.
4. Proprietary data
NEJM Group journal content and multimedia from 1990 onward across NEJM, NEJM Evidence, NEJM AI, NEJM Catalyst and NEJM Journal Watch. Historical depth: Content and multimedia from 1990 onward are explicitly in scope.. Refreshability: Ongoing refresh obligations and the exact delivered corpus are not disclosed..
5. Rights and restrictions
permitted to inform answers delivered on OpenEvidence under the multi-year content agreement Ownership: not disclosed. Training: not disclosed. Post-training: not disclosed.
6. Why the data matters for AI
The licensed content supports retrieval and source-grounded output. No recipient-accessible repeated context/intervention/outcome structure is established by this announcement.
7. Asset Score — Pending/100
Only documented AI use and bounded rights usability are assessed. Evidence for remaining comparative corpus or transaction factors is insufficient; coverage remains below the locked 70% threshold and no total score is published. Score coverage: 14%.
| Factor | Weight | Rating / 5 | Points |
|---|---|---|---|
| Uniqueness / scarcity | 12 | Unknown | — |
| Historical depth | 8 | Unknown | — |
| Decision → outcome richness | 13 | Unknown | — |
| Decision Value Density | 13 | Unknown | — |
| Real-world grounding | 10 | Unknown | — |
| Domain economic value | 9 | Unknown | — |
| Refreshability | 8 | Unknown | — |
| Proprietary advantage | 9 | Unknown | — |
| Model-learning usefulness | 10 | 3.5 | 7.0 |
| Non-replicability | 4 | Unknown | — |
| Rights usability | 4 | 3 | 2.4 |
8. Transaction Signal Score — Pending/100
Only documented AI use and bounded rights usability are assessed. Evidence for remaining comparative corpus or transaction factors is insufficient; coverage remains below the locked 70% threshold and no total score is published. Score coverage: 26%.
| Factor | Weight | Rating / 5 | Points |
|---|---|---|---|
| Disclosed economics | 16 | Unknown | — |
| Clean price discovery | 16 | Unknown | — |
| Separability of data consideration | 15 | Unknown | — |
| Explicit training / model-improvement use | 14 | 3 | 8.4 |
| Clarity of rights purchased | 12 | 3 | 7.2 |
| Competing bids | 10 | Unknown | — |
| Strategic buyer quality | 6 | Unknown | — |
| Repeatability / precedent value | 6 | Unknown | — |
| Independent model-uplift evidence | 5 | Unknown | — |
9. M&A / valuation implications
Analysis: this is evidence of a governed external-asset arrangement, not a standalone valuation comparable without separable economics.
10. Evidence boundary
Strict qualification rests on the defined external corpus and separately material licensed, research or acquired rights, rather than ordinary internal AI deployment. Date is public announcement. Do not treat the simultaneous financing valuation as a content-license price. Issuer separately describes models trained on NEJM content, but the new license's full training terms are not published. Funding valuation is not content-license consideration. Rights not expressly established remain not_disclosed. This historical addition is not a new November announcement.